MAIA Biotechnology Files 8-K
Ticker: MAIA · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1878313
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
MAIA Bio filed an 8-K on 12/23/24, but details are scarce in this snippet.
AI Summary
MAIA Biotechnology, Inc. filed an 8-K on December 23, 2024, reporting other events and financial statements/exhibits. The filing does not contain specific financial figures or details about the 'other events' within the provided text.
Why It Matters
This filing indicates MAIA Biotechnology, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific operational, financial, or strategic information that would indicate a high risk.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- December 23, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-41455 (identifier) — Commission File Number
- 444 West Lake Street, Suite 1700 (address) — Principal Executive Offices
- Chicago, IL (location) — Principal Executive Offices City/State
- 60606 (zip_code) — Principal Executive Offices Zip Code
- (312) 416-8592 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by MAIA Biotechnology, Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events'.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated December 23, 2024.
Where is MAIA Biotechnology, Inc. incorporated?
MAIA Biotechnology, Inc. is incorporated in Delaware.
What is the Commission File Number for MAIA Biotechnology, Inc.?
The Commission File Number is 001-41455.
What is the business address and phone number for MAIA Biotechnology, Inc.?
The business address is 444 West Lake Street, Suite 1700, Chicago, IL 60606, and the phone number is (312) 416-8592.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-12-23 16:51:31
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Common Stock") issuable
- $11,280,000 — ht & Co., dated February 14, 2024, from $11,280,000 to $30,000,000 and filed a prospectus s
- $30,000,000 — February 14, 2024, from $11,280,000 to $30,000,000 and filed a prospectus supplement (the
Filing Documents
- d666778d8k.htm (8-K) — 25KB
- d666778dex51.htm (EX-5.1) — 12KB
- g666778g1221055905285.jpg (GRAPHIC) — 4KB
- 0001193125-24-284263.txt ( ) — 168KB
- maia-20241223.xsd (EX-101.SCH) — 3KB
- maia-20241223_lab.xml (EX-101.LAB) — 18KB
- maia-20241223_pre.xml (EX-101.PRE) — 11KB
- d666778d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 5.1 Opinion of Sheppard Mullin Richter & Hampton LLP 23.1 Consent of Sheppard Mullin Richter & Hampton LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 23, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3